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TInhaled prostacyclin is safe, effective,
and affordable in patients with
pulmonary hypertension, right-heart
dysfunction, and refractory hypoxemia
after cardiothoracic surgery
To the Editor:
We read with interest the elegant article by
De Wet and associates,1 who demonstrated
that inhaled prostacyclin (PGI2) prevents
pulmonary hypertension, right-heart dys-
function, and refractory hypoxemia after
cardiothoracic surgery. We would like to
add some observations regarding the mech-
anisms of action that might be of interest
and of possible value in the further clinical
implementation of inhalational PGI2.
First, pulmonary hypertension is associ-
ated with increased superoxide (O2·-) forma-
tion that is largely mediated by an upregula-
tion of intravascular reduced nicotinamide
adenine dinucleotide phosphate (NADPH)
oxidase.2-5 O2·- reacts with endogenous nitric
oxide (NO) to form reactive nitrogen species,
which effectively reduces NO bioavailabil-
ity.2 Because NO is a vasodilator and an
inhibitor of inflammation, the reduction of
NO formation is considered axiomatic in pul-
monary hypertension.2
O2·- also reduces endogenous vascular
PGI2 formation.3 We recently demonstrated
that the PGI2 analogue iloprost is a potent
inhibitor of NADPH oxidase expression and
activity in porcine pulmonary arteries and
therefore of O2·- formation.3 Therefore by
reducing O2·- formation, PGI2 protects and
enhances NO formation, which itself inhibits
NADPH oxidase.4 The reduction of O2·- also
prevents the formation of isoprostanes, which
are vaconstrictors and promoters of NADPH
oxidase expression.3
One interesting facet of the effect of in-
halational PGI2 reported by De Wet and as-
sociates1 was that it prevented refractory hy-
poxemia. We found that hypoxia promotes
the expression of NADPH oxidase in porcine
pulmonary arteries.5 Hypoxemia, by promot-
ing O2·- formation, would create a self-per-
petuating cascade that would worsen hyper-
tension and further augment hypoxemia.
PGI2, by blocking the expression of NAPDH
he Journal of Thoracic and Cardiovascularoxidase, might break this cycle and protect
the pulmonary vasculature during surgical in-
tervention through this antioxidant mecha-
nism. Inhalational PGI2 might also prevent
perioperative and postoperative intrapulmo-
nary inflammation because PGI2 prevents the
adhesion of leukocytes and platelets to vas-
cular walls.6 Similarly, the preservation of
intrapulmonary NO-forming capacity would
also afford protection against inflammation
because NO has similar anti-inflammatory
properties to PGI2.7 This is of importance
because leukocytes and platelets release va-
soconstrictors and inflammogens, including
thromboxane A2 and cytokines, all of which
upregulate the expression of NADPH oxi-
dase and the formation of O2·-.2-4
The beneficial effect of inhalational
PGI2 on left ventricular function reported
by De Wet and associates1 could be re-
lated to its antioxidative effect on the
lungs. There is substantial evidence that
reactive oxygen species, including O2·
and peroxynitrite, impair left ventricular
function.8 Thus it is reasonable to sug-
gest that the suppression of intrapulmo-
nary oxygen free radical formation by
PGI2 might contribute to the beneficial
downstream protective effect of the pro-
stanoid on the left ventricle.
Finally, in a broader context the admin-
istration of the stable analogue iloprost in
cardiac surgery might be indicated for
other more long-term conditions. In partic-
ular, PGI2 has been shown to inhibit vas-
cular smooth muscle cell proliferation and
migration, platelet and leukocyte adhesion,
and metalloproteinase expression,6 all key
components of vein graft disease. As such,
iloprost might be useful in preventing vein
graft failure.
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Letter to the Editor
Henry T. Bahnson, Hopkins, and
harmonica
To the Editor:
Like many of Henry T. Bahnson’s surgi-
cal peers at Johns Hopkins who were
cited in the in memoriam article by Grif-
fith,1 I was privileged to be a close car-
diology colleague of Hank at Hopkins.
My association with Hank was primarily
through my work in the cardiac catheter-
ization laboratory at Hopkins. At that
time, the cardiac catheterization labora-
tory was under the department of surgery
because the laboratory was considered as
a preoperative diagnostic facility before
950 The Journal of Thoracic and Cardiovapatients, young and old, were operated on
for their congenital and acquired heart
diseases by Blalock and associates. I was
a fellow in the respiratory laboratory of
the late Dr Richard L. Riley, who ar-
ranged with Blalock to let me work 1 day
a week in the cardiac catheterization lab-
oratory because Riley knew of my inter-
est in cardiac catheterization. I still re-
member the few times that I needed some
advice from Hank during cardiac cathe-
terization of babies. I asked the nurse to
page H.T.B. for me. She immediately
tried to correct me by saying, “Do you
mean H.B.T.?” H.B.T. stood for Helen B.
Taussig, of the Blalock-Taussig opera-
tion, and H.T.B. stood for Henry T.
Bahnson. Because the patient was a baby,
it was natural for the nurse to think I
wanted to speak to Helen B. Taussig
rather than to Henry T. Bahnson.
Because Griffith’s article began and
ended with a reference to Bahnson’s har-
scular Surgery ● December 2004monica, I wish to amplify a bit on Hank’s
association with this musical instrument.
As Griffith1 mentioned, The Wall Street
Journal in 1999 published an article titled
“Of artificial hearts and artificial harps in a
Pittsburgh laboratory,” with the subtitle
“Cardiac surgeon and bioengineer study
a harmonica virtuoso from inside his
mouth.”2 The reporter mentioned Hank’s
application of his artificial heart experience
to that of artificial harps, more commonly
known as the harmonica. Because many of
your readers might not be familiar with
publication number 250 in Hank’s bibliog-
raphy mentioned in Griffith’s article, I wish
to mention that the article by Hank was
published in the Journal of the Acoustical
Society of America (Figure 1).3 I suggest
that everyone read the entire article to un-
derstand the history, physics, and physiol-
ogy of the harmonica. As Hank said at the
end of his article, “This helps keep theFigure 1. Top portion of the first page of the article on the harmonica by Bahnson, Antaki,
and Beery3 published 3 years before his death. My initials are T.O., commonly used by my
colleagues at Hopkins. (From Bahnson HT, Antaki JF, Beery QC. Acoustical and physical
dynamics of the diatonic harmonica. J Acoust Soc Am. 1998;103:2134-44. Published with
the permission of the Journal of the Acoustical Society of America, American Institute ofharmonica interesting, and indeed has
